Class II · ModerateActive recall
Duloxetine Delayed-Release Capsules USP
Could cause temporary or reversible harm; serious harm is unlikely.
Does this affect you?
Check your lot numberLot DT6023061B Exp 01/31/2025
Where it was soldNationwide in the USA
Find the lot number printed on your box or bottle. If it matches — and you take this medicine — call your pharmacist. Don't stop a prescribed medicine on your own.
What happened
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
What to do
- Check the lot number and expiry on your medicine against the recall above.
- Talk to your pharmacist or doctor before changing anything — don't stop on your own.
- Report any problems to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
Who makes it
Made byAurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories foreign manufacturer
| Distributed by / for | Amerisource Health Services LLC |
| NDC | 68001-415-04 |
Show the full FDA record
| Full product label | Duloxetine Delayed-Release Capsules USP, 60 mg, Rx only, 30 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-415-04 |
| Recalling firm | Amerisource Health Services LLC |
| Distribution | Nationwide in the USA |
| Quantity | 20,734 30-count bottles |
| Recall initiated | 2024-12-06 |
| Report date | 2025-01-01 |
| Recall completed | — |
| Recall number | D-0157-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Columbus OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗
This is public FDA recall information, not medical advice. A recall does not always mean your specific bottle is affected. Never stop a prescribed medicine without asking your pharmacist or doctor.